Global COVID-19 Clinical Platform: Case Record Form for suspected cases of Multisystem inflammatory syndrome (MIS) in children and adolescents temporally related to COVID-19
The latest update (28 January 2021) includes the following addition and revision:
biosafety aspects for working with antigen-detecting rapid diagnostic test;
handling new variants of SARS-CoV-2 in the laboratory;
updated assay decontamination before disposal;
personal protectiv...e equipment (PPE) for specimen collection;
addressing chemical hazards and their safe disposal; and
the fourth edition of the WHO Laboratory Biosafety Manual (LBM4) is now available and the terminology in this guidance was aligned with the LBM4.
more
OpenWHO is an interactive, web-based, knowledge-transfer platform offering free online courses to improve the response to health emergencies. COVID-19 resources are available in the official WHO languages and in additional national languages .The OpenWHO team is continuing to work with WHO ...Country Offices, public health institutes and educational entities who haveoffered voluntary translation support to help localize the response efforts. Resources in the pipeline include courses in Hindi and Macedonian.
more
Accessed 18 June 2018 | Last updated 1-Jun.-2018 (data as of 25-May-2018) | Next overall update Mid-July 2018
28 January 2021. The purpose of this document is to provide interim guidance on laboratory biosafety related to the testing of clinical specimens of patients.
July 2019
National Malaria Elimination & Aedes Transmitted Disease Control Program
Disease Control Division
Derectorate General of Health Services
The purpose of this document is to provide guidance on the use of pooled sample testing strategy in coronavirus disease (COVID-19)
testing laboratories of the African Union Member States for scaling up SARS-CoV-2 nucleic acid testing capacity with the available resources. The current document descr...ibes the effect of factors such as the prevalence of COVID-19 in the population to be tested, the homogeneity of pools, and the sensitivity of the molecular test in optimal pool size determination. It also highlights the importance of monitoring the prevalence of COVID-19 in a population to be tested and proper validation of the test, to limit the potential for false-negative results. Validation studies to determine the optimal pool size by testing laboratories are recommended as the optimum approach. A safe, simple ‘two-stage pooling’ option has been indicated in this guidance to be used by laboratories until such validation can be achieved.
more
Diagnostics 2019, 9(4), 204; https://doi.org/10.3390/diagnostics9040204
Plateforme mondiale de données cliniques sur la COVID-19 : cahier d’observation pour les cas suspects de syndrome inflammatoire multisystémiqueprésentant un lien temporel avec la COVID-19 chez les enfants et les adolescents
Guidance for health care workers.
Both the REGN-EB3 and mAb114 are recommended for use in EVD. The two drugs should not be given together. The choice of which monoclonal antibody to use depends on availability, including emerging information about effectiveness.